title: Cognition in schizophrenia: summary Nice Consultation Meeting 2012.
authors.forename: David
authors.initials: D
authors.lastname: Nutt
authors.forename: Christine C
authors.initials: CC
authors.lastname: Gispen-de Wied
authors.forename: Celso
authors.initials: C
authors.lastname: Arango
authors.forename: Richard S E
authors.initials: RS
authors.lastname: Keefe
authors.forename: Rafael
authors.initials: R
authors.lastname: Penadés
authors.forename: Declan G
authors.initials: DG
authors.lastname: Murphy
authors.forename: Trevor W
authors.initials: TW
authors.lastname: Robbins
authors.forename: Barbara J
authors.initials: BJ
authors.lastname: Sahakian
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003072:Cognition Disorders / Q000209:etiology / Q000517:prevention & control*; D005060:Europe; D006801:Humans; D009474:Neurons / Q000187:drug effects / Q000378:metabolism; D017410:Practice Guidelines as Topic; D017397:Prefrontal Cortex / Q000187:drug effects / Q000378:metabolism; D012559:Schizophrenia / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology
chemical_list: D014150:Antipsychotic Agents